Elicio Therapeutics IncNASDAQ:ELTX
- LAST PRICE8.9900
- TODAY'S CHANGE (%)-0.1100 (-1.2088%)
- Bid / Lots7.6000/ 1
- Ask / Lots10.0000/ 5
- Open / Previous Close9.1500 / 9.1000
- Day Range
- 52 Week Range
- Volume37,127
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ELTX |
|---|---|---|
| 09:32 ET | 4833 | 9.15 |
| 09:34 ET | 614 | 9.08 |
| 09:43 ET | 100 | 9.03 |
| 10:10 ET | 100 | 9.03 |
| 10:19 ET | 300 | 9.03 |
| 10:26 ET | 105 | 9.03 |
| 10:48 ET | 2212 | 9.03 |
| 11:00 ET | 400 | 9.04 |
| 11:02 ET | 300 | 8.95 |
| 11:04 ET | 400 | 9 |
| 11:15 ET | 100 | 9.06 |
| 11:47 ET | 1100 | 9.06 |
| 12:03 ET | 1000 | 8.9143 |
| 12:07 ET | 214 | 8.9508 |
| 12:09 ET | 176 | 9 |
| 12:12 ET | 1240 | 9.09 |
| 01:14 ET | 100 | 8.925 |
| 01:32 ET | 100 | 8.945 |
| 01:39 ET | 200 | 8.9441 |
| 02:26 ET | 100 | 8.96 |
| 02:51 ET | 900 | 8.89 |
| 03:05 ET | 100 | 8.9 |
| 03:07 ET | 100 | 8.94 |
| 03:09 ET | 100 | 9.09 |
| 03:12 ET | 948 | 8.93 |
| 03:14 ET | 434 | 8.93 |
| 03:16 ET | 100 | 8.93 |
| 03:20 ET | 850 | 9.1 |
| 03:21 ET | 1600 | 8.95 |
| 03:23 ET | 1400 | 8.9402 |
| 03:25 ET | 3000 | 8.9294 |
| 03:39 ET | 1648 | 8.955 |
| 03:41 ET | 1000 | 8.9199 |
| 03:45 ET | 700 | 8.8728 |
| 03:48 ET | 1000 | 9.02 |
| 03:50 ET | 797 | 8.95 |
| 03:52 ET | 698 | 8.9414 |
| 03:54 ET | 1052 | 8.85 |
| 03:56 ET | 645 | 8.83 |
| 03:59 ET | 251 | 8.99 |
Apr 25, 2024
Apr 5, 2024
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting, from 4:30PM ET on Friday Apr 05, 2024 by Dow Jones
4:30PM ET on Friday Apr 05, 2024 by Dow Jones
Mar 29, 2024
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates, from 8:30AM ET on Friday Mar 29, 2024 by Dow Jones
8:30AM ET on Friday Mar 29, 2024 by Dow JonesPress Release: Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates, from 8:30AM ET on Friday Mar 29, 2024 by Dow Jones
8:30AM ET on Friday Mar 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Elicio Therapeutics Inc | 92.0M | -1.0x | --- |
Allovir Inc | 90.9M | -0.4x | --- |
IO Biotech Inc | 93.6M | -0.7x | --- |
Genelux Corp | 91.3M | -2.8x | --- |
PMV Pharmaceuticals Inc | 90.0M | -1.2x | --- |
Allakos Inc | 89.6M | -0.5x | --- |
Company Information
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). Its ELI-007, is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers. Its AMP platform has broad potential applications for the treatment or prevention of cancer, infectious diseases and other diseases.
Contact Information
- Headquarters
- 451 D Street, 5Th FloorBOSTON, MA, United States 02459
- Phone
- 857-209-0050
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Julian Adams
- President, Chief Executive Officer, Director
- Robert Connelly
- Chief Financial Officer
- Brian Piekos
- Executive Vice President - Head of Research and Development, Chief Medical Officer
- Christopher Haqq
- Chief Scientific Officer
- Peter Demuth
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $92.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-8.81 |
Book Value | $1.18 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
